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Abstract
Background: Achieving the Millennium Development Goals for health requires a massive scaling-
up of interventions in Sub Saharan Africa. Intermittent Preventive Treatment in infants (IPTi) is a
promising new tool for malaria control. Although efficacy information is available for many
interventions, there is a dearth of data on the resources required for scaling up of health
interventions.
Method: We worked in partnership with the Ministry of Health and Social Welfare (MoHSW) to
develop an IPTi strategy that could be implemented and managed by routine health services. We
tracked health system and other costs of (1) developing the strategy and (2) maintaining routine
implementation of the strategy in five districts in southern Tanzania. Financial costs were extracted
and summarized from a costing template and semi-structured interviews were conducted with key
informants to record time and resources spent on IPTi activities.
Results: The estimated financial cost to start-up and run IPTi in the whole of Tanzania in 2005 was
US$1,486,284. Start-up costs of US$36,363 were incurred at the national level, mainly on the
development of Behaviour Change Communication (BCC) materials, stakeholders' meetings and
other consultations. The annual running cost at national level for intervention management and
monitoring and drug purchase was estimated at US$459,096. Start-up costs at the district level
were US$7,885 per district, mainly expenditure on training. Annual running costs were US$170 per
district, mainly for printing of BCC materials. There was no incremental financial expenditure
needed to deliver the intervention in health facilities as supplies were delivered alongside routine
vaccinations and available health workers performed the activities without working overtime. The
economic cost was estimated at 23 US cents per IPTi dose delivered.
Conclusion: The costs presented here show the order of magnitude of expenditures needed to
initiate and to implement IPTi at national scale in settings with high Expanded Programme on
Immunization (EPI) coverage. The IPTi intervention appears to be affordable even within the budget
constraints of Ministries of Health of most sub-Saharan African countries.
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Background
A massive scaling-up of health interventions is required
over the coming years[1] if sub-Saharan Africa is to reach
the health-related Millennium Development Goals
(MDG). Efficacy information is available for key interven-
tions[2] but there is a dearth of information on the
resources required for implementation of interventions
known to be cost-effective. In recent years costing infor-
mation has been an integral part of health intervention
evaluation as it is vital for management, prioritization and
scaling-up of health interventions[3].
Successful scaling-up of a health intervention is based on
two prerequisites: first is the development of an effective
delivery and management system at various levels and
second is the longer-term implementation of the interven-
tion based on a good knowledge of costs and sound
financing strategies. In this study, we costed the resources
required to set up integrated management and implemen-
tation systems for an intervention to use an existing plat-
form of routine health service delivery. In recent years
economists have published a number of costing studies of
malaria control interventions, some concerning new
interventions[4], some on the cost of existing interven-
tions [5-8] and others on program administrative cost or
policy change [9-11]. Few published studies[4,10] esti-
mated both the cost of developing a delivery strategy and
the incremental costs of incorporating an intervention
into the routine health system.
Intermittent Preventive Malaria Treatment in infants
(IPTi) is a promising tool to fight malaria [12-16]. Efforts
are underway through the IPTi Consortium to generate
evidence on the safety, efficacy, acceptability and cost-
effectiveness of IPTi in a range of settings so as to inform
a policy recommendation http://www.ipti-malaria.org. If
IPTi is recommended as a policy, the next challenge will
be to transform this intervention into public health action
in a reasonable timeframe. This requires a well developed
delivery strategy and information on resources required.
In Southern Tanzania, local IPTi safety and efficacy data
were available in 2001[15] and there was interest to
explore the operational issues surrounding large-scale
implementation as part of an integrated district-based
approach to control malaria. Together with the Ministry
of Health and other partners, a strategy for the delivery of
IPTi was developed, implemented and evaluated between
2004 and 2008. These activities enabled a parallel costing
study to produce realistic estimates of the costs of devel-
oping the delivery strategy, and of implementing and
maintaining it. In contrast to many costing studies, few
assumptions were needed as economic costs were simply
tracked during the development and implementation
phases. For example, we included administrative costs
important for decision making and implementation such
as stakeholder consultations, adapting the health infor-
mation system and developing behavior change commu-
nication materials for the strategy. The study was designed
to enable us to answer the question "What resources are
needed to implement IPTi?", something asked by policy
implementers at district level, such as Council Health
Management Teams (CHMTs) in Tanzania. This study
therefore provides insights into the budget implications of
scaling-up IPTi and prepares the way for identifying future
financing options.
Methods
Background
A Tanzanian district is administered at the 3rd level of the
government hierarchy, and is also called a Local Govern-
ment Authority. The district's main purpose is to
empower the people to participate in the planning and
implementation of local development programmes. In
terms of health objectives, a district is a focal point for the
planning, delivery and evaluation of health services. Dis-
tricts mobilize, manage and account for government
health resources and deliver health services in line with
their own plans and budget allocations.
Health financing in Tanzania involves central government
(Ministry of Health and Social Welfare – MoHSW), house-
holds, donors, NGO's and private firms. In 1999/2000,
households provided the greatest proportion of health
care financing (47%), followed by donors (23%), govern-
ment (22%), NGOs (5%) and firms (3%)[17]. Govern-
ment spending on health in Tanzania has increased in
recent years standing at US$369 million in 2006 (US$
9.92 per capita) which represents 11.6% of overall gov-
ernment spending (Table 1)[18]. Health sector spending
is financed from block grants which are sourced from the
Tanzanian government and the health 'basket' fund which
is contributed to by donors.
A Comprehensive Council Health Plan (CCHP) brings
together annual plans and details the provision of accessi-
ble, quality health care services for local communities.
These include cost effective interventions developed
according to the Essential Health Package (EHP) and in
line with the National Health Policy. The CCHP is sup-
ported by Local Health Block Grants and the Health Bas-
ket Grants based on criteria of population size (70% of
the grant value), vehicle mileage (10%), poverty status
(10%) and under five mortality rates (10%)[19]. These
criteria are important in the sense that the individual is
recognized as the main client of the health service, with
children aged under five years and pregnant women rec-
ognized as the most vulnerable for many health issues.
The mileage criterion takes into account the higher opera-
tional cost of delivering health services to a rural popula-
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tion and to scarcely populated areas, including the higher
costs faced in drug distribution, immunization services
and supervision. The under-five mortality criterion directs
increased resources to places with higher burden of dis-
eases. The CCHP is drafted by the planning team at the
district level and then passed to the Regional Secretariat
before approval is sought from the district council, the
President's Office for Regional Administration and Local
Government and the MoHSW. At the national level,
checks are made for adherence to national guidelines, to
make sure the plan meets both financial and technical
performance requirements for funding.
Study area
The Southern Tanzania IPTi effectiveness study is being
conducted in five districts across two regions: Lindi Rural,
Nachingwea and Ruangwa districts in Lindi region, and
Tandahimba and Newala districts in Mtwara region. A
detailed explanation is given elsewhere[20]. Briefly, the
population of this poor, rural area is around 900,000 and
subject to the highest infant mortality rate in the country
at around 121 per 1,000 live births compared to national
average of 68 per 1,000 live births[21,22]. Like the rest of
Tanzania, the health system in the project area comprises
a network of tiered public and private facilities where IPTi
is delivered alongside Expanded Programme on Immuni-
zation (EPI) services. The EPI vaccine coverage is high,
with 80–90% of all children aged 12–23 months receiving
BCG, DPT and OPV before one year of age [20]. In 2006
the health facilities in the project area comprised seven
hospitals, 13 health centres and 131 dispensaries. The
project districts are further divided into 24 divisions and
IPTi implementation was initiated in half of these divi-
sions. National policy dictates that children and pregnant
women should not pay for health services.
The intervention and the delivery strategy
This study was a large scale community-randomised trial,
which compared sets of process and outcome indicators
between 12 IPTi-implementing divisions and 12 compar-
ison divisions. The IPTi intervention is the delivery of a
treatment dose of sulphadoxine-pyrimethamine (SP) to
infants attending Reproductive and Child Health clinics
for vaccination at three points in time: doses two and
three of DTP/hep B/OPV, and the measles vaccine, corre-
sponding to approximately 2, 3 and 9 months of age. An
infant is given a quarter tablet of SP if they weigh under 5
Kg or a half tablet if they weigh 5 kg or over.
In order to achieve high and sustainable coverage of IPTi
as part of routine preventive health services for infants, a
number of elements are required that together constitute
the IPTi strategy. The IPTi strategy was developed in close
collaboration with the Ministry of Health and Social Wel-
fare (MoHSW) to ensure that it would be feasible to roll
out across the whole country should a policy decision be
taken to implement IPTi nationally. The Expanded Pro-
gramme on Immunization (EPI) which is well established
in Tanzania was used as the vehicle for IPTi delivery. IPTi
has been implemented by routine health workers. Rou-
tine health workers were trained to explain the IPTi inter-
vention to mothers attending the EPI clinic with their
infants, to raise community awareness on intervention
more generally, and to deliver and document doses of IPTi
using modified EPI monitoring tools alongside vaccina-
tions in health facilities. The CHMT through the District
Cold Chain Officer and Reproductive and Child Health
Coordinator were equipped with adequate and specific
tools to manage the requisition and supply of IPTi-related
materials.
Costing: methods
One important distinction made in this study is between
two types of health system cost: the cost of developing a
delivery system for IPTi, which is mainly incurred at
national level, and the cost of implementing IPTi, which
is mainly incurred at the district level and below.
Costs were classified into different components, namely
strategy development and sensitization; BCC material
development; SP purchase and distribution; training;
administration of the intervention in health facilities, and
strategy management. A description of each is provided in
Table 2.
Table 1: Health resources in Tanzania for year 2003 – 2006
Item Year
2003 2004 2005 2006a
Health as percentage of overall government spendingb 12.9% 10.0% 10.9% 11.6%
Level of spending on health (millions) US$172 US$200 US$261 US$369
Population estimates 34,155,840 35,146,359 36,165,604 37,214,406
Per capita health spending US$5.04 US$5.70 US$7.21 US$9.92
aBudget bExcluding consolidated fund services (CFS).
Source: United Republic of Tanzania. Ministry of health. Health sector PER update FY06. Final Report. September 2006.
BMC Health Services Research 2008, 8:165 http://www.biomedcentral.com/1472-6963/8/165
Page 4 of 9
(page number not for citation purposes)
District level total costs and IPTi delivery unit costs were
estimated from the health system perspective. Four differ-
ent health system levels were considered – national,
regional, district and health facility. However, regions
have only a minor role in health system financing and
that role is closer to the district than national role, and
thus we summarized regional cost estimates to district
level. District implementation costs thus reflect activities
undertaken at regional, district and health facility levels.
National level costs include all activities organized by the
MoHSW and are mainly related to policy matters. Given
that a scaled up strategy would be country-wide, the esti-
mated costs of strategy change were allocated across the
total number of districts in Tanzania. IPTi dose forecasts
were based on current EPI coverage levels.
A costing template enabled detailed costs to be captured
relating to each IPTi development and implementation
activity. Expenditure on formal meetings and training was
tracked by use of specific cost centres in the accounting
software which were later reviewed to extract financial
costs. Semi-structured interviews were conducted with
nine key informants involved in early IPTi activities
including formal meetings, informal meetings and inde-
pendent desk work. These were IPTi investigators and sup-
port staff who were interviewed by one of us (FM) at their
convenience according to a discussion guide. The reported
time spent was used to derive estimates of financial and
opportunity costs related to human resources for IPTi
strategy development and implementation. Informal
activities included consultations with key stakeholders
which did not involve hiring meeting rooms. Desk work
included the value of time spent by individuals in prepa-
ration, designing, brainstorming or organizing project
activities. A summary sheet (table 2) was used to guide
summarizing of data according to the activity components
and health system level, with a distinction made between
financial and non-financial 'opportunity' costs.
Table 2: Components of implementation
1. Policy change and Sensitization
Policy change activities include planning, policy related consultations. Sensitization activities include meetings with stakeholders. Both policy change 
and sensitization involves working with a broad group of stakeholders at national and international organizations, a more focused IPTi core group of 
key stakeholders and district level health managers. These costs were incurred at the start of implementation.
2. Development of Behaviour Change Communication (BCC) materials
This was incurred before the start of implementation, but also includes minor recurrent costs related to occasional replacement of materials. 
Activities include development of materials (eg training leaflet, job aid, and posters), pilot testing, production and distribution.
3. SP purchase and distribution
This is mainly a recurrent cost. Purchase activities include importation and overhead costs of arranging importation. Distribution activities involve 
the distribution from port to Medical Stores Department (MSD), then to regional level, district level and finally to health facilities.
4. Training
This is mainly incurred at the start of implementation but also includes refresher and new staff training. The training involves training trainers at 
regional and district levels in strategy change, BCC and IPTi administration. In turn, these trainers train the front-line health facility staff.
5. Administration of the intervention in health facilities
This is a recurrent cost. It involves SP provision: preparation, administration to children, recording dosage and dates in immunization cards and 
books of the Health Management Information System (HMIS) by health workers at facilities. It also includes education of mothers about IPTi. This 
was calculated as the proportion of an RCH nurse's gross salary spent on IPTi per year at implementing facilities in the 5 study districts.
6. Strategy management
This is incurred partly at the start of implementation, and partly as an ongoing activity. The start-up costs are converted to annual costs assuming a 
10 year intervention period. In the case of the Southern Tanzania project, it involved the recruitment of a public health professional to support the 
implementation activities. It also included consultations with regard to adaptation of HMIS and immunization cards, as well as printing costs.
Note that components 1 and 2 are sometimes referred to as administrative or higher level costs. They involve activities to get the intervention 
developed and implemented by the routine health system. The costs were spread over 10 years which is the expected lifetime of a national 
program
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Opportunity costs were those that were diverted from
other uses or were not fully employed and therefore using
up slack (inefficiencies) in the system. Financial costs
were those that involved direct budgetary impacts – in
other words, financial payments. This cost classification
was important with regard to using our estimates in other
settings, as health systems financing and configuration
differ widely across sub-Saharan Africa. Whereas in one
setting the health system might have in-house expertise at
the Ministry of Health, others might need external exper-
tise – with a need for additional financial resources. The
total cost, which is the estimated economic cost, is the
sum of financial costs and non-financial (opportunity)
costs. Cost classification was based on how related activi-
ties are usually done, and how they are valued, under a
MoHSW-led program. There were no fixed assets pur-
chased specifically for IPTi, but we accounted for hired
fixed assets under transport and buildings. The costing
estimates reflect a one year time frame.
Ethical clearance
This study received ethical approval from the institutional
review boards of the Ifakara Health Research and Devel-
opment Centre, the National Tanzania Medical Research
Co-coordinating Committee, the Tanzania Commission
for Science and Technology, and the London School of
Hygiene and Tropical Medicine. During field work, infor-
mation sheets about the study in Swahili were distributed,
explaining why it was being carried out, by whom, and
what it would involve. Verbal informed consent was
obtained from all study participants and confidentiality
was assured.
Sensitivity analysis
This costing study started at the beginning of the main
IPTi project in 2004 and was completed in 2007. Excel
spreadsheets were used to conduct sensitivity analyses on
key variables that were susceptible to change over time or
in different settings. These include EPI coverage, SP brand,
inclusion of community sensitization (differentiating the
intervention delivery by researchers and that by MoHSW),
and changes in human resource cost due to recent
increases in per diem rates and salaries for health staff in
Tanzania.
Results
The costs per district of developing the IPTi strategy and of
implementation for the first year, are summarized in addi-
tional file 1. This total cost is broken down into the appor-
tioned cost per district of national level activities and the
cost per district of activities at district level or below. Costs
were split into personnel, transport and materials and
buildings.
The single largest expenditure was for training which cost
US$7,392 per district, 51% of the total start-up and year
one costs. There was no incremental financial expenditure
needed to deliver the intervention in health facilities as
available health workers performed the activities without
working overtime. The other major intervention related
cost was for drug purchase and distribution, some
US$3,538 per district (24%). National development
related costs were relatively modest when shared amongst
the districts; Behaviour Change Communication (BCC)
cost US$175 per district (1.2%). Simulated policy change
and sensitization was US$56 per district (0.4%) and man-
agement and monitoring cost US$309 (2%) per district.
In terms of cost category, personnel costs amounted to
US$6,693 (46% of the total cost), mainly for training
(US$4,285) and sensitization (US$1,549). Of the total
personnel cost, US$3,746 (56%) was incremental finan-
cial expenditure. The cost of transport was US$3,949
(27% of the total cost), again mainly for training
(US$2,746) and sensitization (US$984). Materials and
building costs accounted for US$3,944 (27% of the total
costs).
Overall, approximately 28% of the costs per district were
for national level activities and the rest were costs per dis-
trict of activities at district level or below.
The unit costs are presented in Table 3. The total cost per
IPTi dose delivered was estimated at 23 US cents, of which
18 US cents (78%) was financial expenditure and 5 US
cents (22%) was opportunity cost.
Table 4 summarizes the estimated financial start-up and
annual running costs of IPTi, first at national level, second
for a single decentralized district, and third to scale up to
the123 districts in the whole country. At national level,
the start-up cost was estimated at US$36,363 involving
development of the strategy including BCC materials,
stakeholders meetings and consultations. The annual run-
ning cost at national level for intervention management
and monitoring and SP drug purchase was estimated at
US$459,096. The start-up cost was US$7,885 per district,
mainly for training of front-line health staff, with an
annual running cost of US$170 per district largely for the
printing of BCC materials. Overall US$1,006,278 would
be required to develop the IPTi strategy and implement it
in the whole country with an additional US$480,006
required to run the intervention across the country for a
year.
Sensitivity analysis
Table 5 shows the results of sensitivity analyses testing the
impact of varying key inputs on the economic costs in the
program. Normally under large scale MoHSW-run pro-
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grams, community sensitization is not included, espe-
cially for introducing a new intervention into the EPI
program. But since the intervention was implemented
through a research programme, it was necessary to intro-
duce researchers through meetings with district health
management teams, district heads of departments and
community representatives (councilors). These sensitiza-
tion activities had some impact on the economic cost,
with an increase of 8%.
The change in human resource remuneration following a
salary increase of 50% for health ministry staff between
2004 and 2006 led to a 17% increase in economic costs
per dose delivered. Reducing the intervention coverage
from 94% (as reported in the 2006 EPI report[23]) to
71%(as reported by the Demographic and Health Survey
2005 [24]) led to a 32% increase in costs per dose deliv-
ered due to the spreading fixed national and district costs
among fewer IPTi recipients. The use of locally manufac-
tured SP had a major impact on unit costs, with unit cost
per dose delivered reduced by 42% from 23 to 13 US
cents, most of which was a saving in financial expendi-
ture. Finally, the most likely scenario of using generic
drug, increasing salaries, excluding sensitization and
lower EPI coverage increased economic cost by 21%.
Discussion
This paper has presented the total costs of developing and
implementing a strategy for the delivery of IPTi. The infor-
mation is based on the actual costs incurred in the devel-
opment of an IPTi strategy in conjunction with national
authorities and implementation by district health teams.
This approach has the advantage of making very few
assumptions as costs were tracked in the course of actual
implementation. The results should nevertheless be inter-
preted with caution. The study activities were undertaken
by researchers, and although an attempt was made to
exclude irrelevant research costs, it is possible that the
researchers influenced programme costs in comparison to
government-led implementation. However, we are confi-
dent that the cost tracking system was detailed enough to
ensure that those costs that were likely to be incurred
under normal programme conditions were identified and
quantified and the sensitivity analysis modeled the effect
of the research team on IPTi costs.
Table 3: Estimated unit cost of IPTi per dose delivered. Figures are United States cents, year 2005 (Tsh1205 = US$1)
Activity component Health
system
level
Financial 
costs
Opportunity 
costs
Total costs
Policy change National 0.01 0.02 0.03
Sensitization District 0.76 1.12 1.88
BCC National 0.03 0.05 0.08
SP purchase and distribution National 12.56 0.26 12.82
Training District 3.06 2.30 5.36
Administration of intervention in health facilities District 0.00 1.25 1.25
Strategy management National 0.65 0.10 0.75
District 0.62 0.00 0.62
Sub-Total National 13.25 0.43 13.68
District 4.44 4.67 9.11
Overall total 17.68 5.11 22.79
Table 4: Summary of estimated financial costs for a national IPTi program in Tanzania: start-up and annual implementation. 
Level Start-up costs
(US$ in 2005)
Running cost
(US$ in 2005)
Cost of IPTi strategy
development & first
year implementation
(US$ in 2005)
Cost at National level 36,363 459,096 69,092
Cost per district 7,885 170 11,522
Sub-total for 123 districts 969,915 20,910 1,417,192
Total for national implementation 1,006,278 480,006 1,486,284
Figures are United States dollars, year 2005 (Tsh.1205 = US$1)
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The cost findings of the key components were consistent
with costing studies of other interventions, although dif-
ferent methodologies were used and different types of
costs presented. For example, as shown by Mulligan and
colleagues (2006)[10], we found that policy related costs
are mainly incurred at national level and that training
accounts for a significant proportion of the total cost at
district level. Other studies have reported that national
level costs for administration and material purchase can
constitute a considerable proportion of scale-up costs in
the short term [9] and their inclusion increases overall
intervention costs. It is therefore important to consider
costs of administration when estimating resource require-
ments for health intervention scale-up.
The unit cost per dose delivered is very low compared with
other interventions such as Insecticides Treated Nets
(ITNs) or Indoor Residual Spraying(IRS)[25,26]. In this
study the cost per IPTi-year of protection (3 doses) was US
69 Cents while the cost per net-year of protection ranged
from US$1.43 to US$6.05 and the cost per IRS-year of
protection ranges from US$3.27 to 3.90[27]. However,
caution is needed in making a direct comparison as the
efficacy of various interventions differs and the costing
studies used different methodologies. The present study,
however, was inclusive in the costs identified and meas-
ured, and hence conclusions on the low unit cost of IPTi
relative to unit costs of other malaria control interven-
tions are likely to be robust.
Delivery of the intervention at facilities involved no finan-
cial resources because excess system capacity was utilized.
In effect the intervention boosted efficiency of resource
use, while it did not appear to add undue strain to the
health system, according to a time and motion study con-
ducted on vaccinating staff in the IPTi study area[28].
Interestingly, IPTi required very few marginal resources
even when administration costs were included. To estab-
lish and implement the IPTi strategy would require 0.4%
of the total health sector budget for 2004/5. Furthermore,
only 1% of a typical district budget would be required to
develop and run the IPTi intervention in its first year. This
might be affordable given the increased global resources
to fight HIV, TB and malaria http://www.theglobal
fund.org.
The cost of IPTi implementation is likely to vary between
countries but the estimates in this paper provide an order
of magnitude of the resources required to initiate and
maintain implementation of IPTi in most sub-Saharan
African settings, especially those with high EPI coverage of
80 per cent or more http://www.unicef.org/immuniza
tion/index_coverage.html. Costs vary between settings
and change over time, such as the level of staff remunera-
tion, travel expenses and drug costs. What has been pre-
sented provides a starting point that could be considered
in the light of available system resources and feed into
rational decision making.
Scaling-up health interventions is essential if the millen-
nium development goal for child mortality (target 4) is to
be met. Strengthening of health system components –
human resources, planning capacity, financing and serv-
ice delivery – is one response to alleviate challenges to
move forward to scale-up interventions. Cost data have
been presented in a synthesized manner to facilitate utili-
zation by users[29]. The distinction between financial and
economic perspectives has implications for health system
resource allocation to achieve greater efficiency. The
financial cost has a direct influence on budgetary actions
and the economic perspective is useful when considering
efficient allocation and re-allocation of resources, espe-
cially those already available and paid for by the health
system. These different cost categories were presented to
support interpretation of total costs and eventual use of
the information by decision makers. The measurement of
full costs and the distinction between cost categories is
important because, although some costs might not
require budget expenditure in one setting, they might do
in another setting due to variation between health sys-
tems.
Conclusion
Actual country-specific data is useful to indicate orders of
magnitude of resource requirements and should facilitate
rational decision making. The incremental financial and
Table 5: Results of sensitivity analysis on the economic cost per IPTi dose delivered. Figures are United States cents, year 2005 
(Tsh1205 = US$1)
Variables Financial Opportunity Economic cost (Total)
Base case results 17.68 5.11 22.79
Low EPI coverage (71% nationwide) 23.41 6.76 30.18
Exclude sensitization at community level 16.92 4.00 20.9
Use of local brand SP Drug 8.44 4.85 13.29
Increase in salaries and per diem 20.97 5.74 26.71
Using generic drug, increasing salaries, excluding sensitization and lower EPI coverage 22.40 5.28 27.68
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opportunity costs needed to initiate and implement IPTi
at national scale show that the intervention is generally
affordable within the budget constraints of Ministries of
Health of sub-Saharan African countries with high EPI
coverage.
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